Adalimumab biosimilar (GlycoNex)

阿达木单抗生物类似药 (台湾糖联生技医药股份有限公司)

Report date: 2024/06/05 11:59:43

Base Information

Drug NameAdalimumab biosimilar (GlycoNex)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsAutoimmune Diseases of the Nervous System
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesGlyconex Inc
China Registration ClassN/A

Develop Information

Active CompaniesGlyconex Inc
Inactive CompaniesN/A
Active IndicationsAutoimmune Diseases of the Nervous System
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A